Ultragenyx Issues 2023 Corporate Responsibility Report,

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with. “In rare disease, corporate responsibility means pushing for progress and change to support drug development and…
Read More…

Source: https://www.globenewswire.com/news-release/2024/04/30/2872737/0/en/Ultragenyx-Issues-2023-Corporate-Responsibility-Report-Showcasing-Commitment-to-Improving-Equity-and-Access-to-Innovation-in-Rare-Disease.html